Related Experiment Video
Updated: Jun 27, 2026

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
Published on: April 7, 2014
Evidence of early subclinical atherosclerosis in women with exercise-induced hypothalamic amenorrhea
Manuel Luque-Ramírez1,2, Sara de Lope Quiñones1, Alejandra Quintero-Tobar1
1Diabetes, Obesity and Human Reproduction Research Group, Instituto Ramón y Cajal de Investigación Sanitaria & Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas &, Universidad de Alcalá, Madrid, Spain.
Study Question:
Do women with exercise-induced functional hypothalamic amenorrhea (Ex-FHA) have an increased risk of subclinical atherosclerosis, as measured by carotid intima-media thickness (cIMT)?
Summary Answer:
Women with Ex-FHA appear to show greater cIMT than non-exercising control women (nonEx-control).
What Is Known Already:
Long-term cardiovascular risk is a major concern in women with functional hypothalamic amenorrhea who exercise regularly. Although hypoestrogenic women with Ex-FHA consistently exhibit markers of risk, such as endothelial dysfunction, evidence of atherosclerosis is lacking.
Study Design Size Duration:
From 2019 to 2025, we conducted a cross-sectional comparative study of five groups of premenopausal adult women (N = 50). According to our calculations, this sample size allowed us to detect a minimum difference of 0.019 mm in common cIMT between any pair of groups, setting α to 0.05 and power (1-β) to 0.80.
Participants/Materials Setting Methods:
We included three groups of women with different mechanisms of ovulatory dysfunction: women with Ex-FHA, women with classic PCOS, and women with non-hyperandrogenic PCOS. Healthy exercising (Ex-control) and nonEx-control served as control groups. Smokers were excluded. All women received a comprehensive cardiometabolic phenotyping including anthropometrics, circulating sex steroids, carbohydrate metabolism and lipid profiles, office and 24-h ambulatory blood pressure monitoring, and cardioautonomic function studies. Ultrasound measurement of mean cIMT served as a marker of subclinical carotid atherosclerosis.
Main Results And The Role Of Chance:
Women with Ex-FHA were the only subgroup of study participants showing higher cIMT values than nonEx-controls [cIMT: 0.514 ± 0.057 vs 0.411 ± 0.054 mm, respectively; mean difference: 0.103 (95% CI: 0.031; 0.175); P = 0.002]. This difference remained after adjusting for BMI. Regarding carbohydrate and lipid metabolism, women with Ex-FHA showed a higher insulin sensitivity index than both subgroups of women with PCOS. Individuals with Ex-FHA had higher concentrations of HDL-cholesterol, HDL-triglycerides, and large- and medium-HDL particles than both subgroups of women with PCOS, Ex-controls, and nonEx-controls. Women with Ex-FHA presented with a lower resting heart rate than participants with classic PCOS, Ex-controls, and nonEx-controls. They also showed a lower diastolic blood pressure response to standing than nonEx-controls.
Limitations Reasons For Caution:
The limited sample size of our study population precluded us from identifying the main determinants of subclinical atherosclerosis in each subgroup of women. The cross-sectional observational design of this study does not allow causal inference regarding associations between independent variables and cIMT. Lastly, multiple comparisons may have led to spurious associations in some cases, despite having implemented rigorous adjustments for multiplicity whenever possible.
Wider Implications Of The Findings:
While data on robust endpoints of women with Ex-FHA are lacking, this novel finding on subclinical carotid atherosclerosis may enhance scientific understanding of their cardiovascular risk profile. Still, larger confirmatory studies are needed with the aim of establishing cIMT as an early marker of atherosclerosis in Ex-FHA and, secondly, clarifying which intrinsic risk factors underlie this association.
Study Funding/Competing Interests:
This research was funded by Instituto de Salud Carlos III grants PI1801122 and PI2100116, and co-funded by the European Union. The authors declare not to have any conflicts of interest.
Trial Registration Number:
ClinicalTrials.gov ID: NCT03841981.
Related Concept Videos
Hypothyroidism II: Pathophysiology
Hyperthyroidism II: Pathophysiology
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Hypothalamic-Pituitary Axis
Coronary Artery Disease III: Clinical Manifestations
